Active	Status	Sponsor type	Region	Phase	Filter
2 Active 1 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
DVC1-0101 / I’rom Group, Shenzhen Salubris
NCT02276937: Randomized Phase IIb Trial of DVC1-0101	Active, not recruiting	2b	30	Japan	DVC1-0101, rSeV/dF expressing human FGF-2 gene	Kyushu University, Ministry of Health, Labour and Welfare, Japan, Japan Agency for Medical Research and Development	Intermittent Claudication, Peripheral Arterial Disease	12/21	08/24
ACTRN12615001144505: A Phase I/IIa Study of DVC1-0101 in Subjects with Intermittent Claudication or Critical Limb Ischaemia Secondary to Peripheral Artery Disease	Terminated	1/2	18			CMAX - a division of IDT Australia, ID Pharma Co. Ltd	Intermittent claudication secondary to peripheral artery disease, Critical limb ischaemia secondary to peripheral artery disease